Wasatch Advisors LP Decreases Position in Intellia Therapeutics, Inc. $NTLA

Wasatch Advisors LP lowered its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 16.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 261,864 shares of the company’s stock after selling 51,821 shares during the period. Wasatch Advisors LP owned approximately 0.22% of Intellia Therapeutics worth $3,357,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Oppenheimer & Co. Inc. lifted its stake in shares of Intellia Therapeutics by 0.8% in the fourth quarter. Oppenheimer & Co. Inc. now owns 105,165 shares of the company’s stock worth $945,000 after acquiring an additional 808 shares in the last quarter. Comerica Bank boosted its holdings in Intellia Therapeutics by 45.8% in the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after purchasing an additional 901 shares during the last quarter. Interchange Capital Partners LLC grew its stake in Intellia Therapeutics by 9.7% during the 3rd quarter. Interchange Capital Partners LLC now owns 11,695 shares of the company’s stock valued at $202,000 after purchasing an additional 1,030 shares in the last quarter. Benjamin Edwards Inc. increased its holdings in Intellia Therapeutics by 1.8% during the 2nd quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock worth $591,000 after purchasing an additional 1,126 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its holdings in Intellia Therapeutics by 8.4% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 17,250 shares of the company’s stock worth $159,000 after purchasing an additional 1,333 shares during the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $16.68 on Friday. The stock has a market cap of $2.33 billion, a price-to-earnings ratio of -4.71 and a beta of 1.92. Intellia Therapeutics, Inc. has a 1 year low of $7.95 and a 1 year high of $28.25. The business has a fifty day moving average of $13.94 and a 200-day moving average of $12.77.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.11. The business had revenue of $15.05 million during the quarter, compared to the consensus estimate of $13.81 million. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. During the same quarter in the prior year, the company posted ($1.10) earnings per share. On average, equities research analysts predict that Intellia Therapeutics, Inc. will post -3.18 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on NTLA. Morgan Stanley boosted their price target on Intellia Therapeutics from $11.00 to $15.00 and gave the company an “equal weight” rating in a report on Monday, April 27th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $49.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, June 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Intellia Therapeutics in a report on Tuesday, April 21st. Wells Fargo & Company lifted their price target on shares of Intellia Therapeutics from $12.00 to $15.00 and gave the company an “equal weight” rating in a report on Tuesday, March 3rd. Finally, Chardan Capital increased their price objective on shares of Intellia Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, April 27th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $20.46.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.